Publication at Second Faculty of Medicine |
2012
Abstract
Type 2 diabetes mellitus (DM2) is a complex progressive metabolic disease that is often accompanied by obesity, hypertension and hyperlipidemia. Pharmacological treatment of DM2 is usually initiated with metformin (along with diet and regimens), which is initially sufficiently effective in monotherapy.
However, with declining β-cell function and disease progression, despite the current wide range of antidiabetics, it is becoming increasingly difficult to select effective and well-tolerated treatments, and other treatments are therefore being sought.